The U.S. Court of Appeals for the Federal Circuit has temporarily halted MSN Pharmaceuticals from launching a generic version of Novartis’ heart-failure medication, Entresto. This decision provides Novartis with a brief respite following a recent unfavorable ruling in a Delaware district court.
On July 11, 2025, U.S. District Judge Richard Andrews in Delaware denied Novartis’ request to prevent MSN from introducing its generic Entresto before the patent’s expiration in November 2026. Judge Andrews concluded that Novartis failed to demonstrate that MSN’s generic would infringe upon its patent. Novartis disclosed that MSN might receive FDA approval for the generic as early as July 16, potentially impacting the market for Entresto, which generated over $7.8 billion in global revenue last year. Following this ruling, Novartis’ stock declined by more than 2%. The company expressed disappointment and announced plans to appeal. ([reuters.com](https://www.reuters.com/legal/litigation/novartis-loses-bid-block-us-entresto-generic-through-2026-2025-07-11/?utm_source=openai))
In response to the Delaware court’s decision, Novartis sought intervention from the Federal Circuit. The appellate court issued an order temporarily blocking MSN from launching its generic while it considers Novartis’ request for a more extended injunction. This move marks the latest development in the ongoing legal battle over Entresto’s market exclusivity. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-appeals-court-lifts-pause-generic-version-novartis-entresto-2025-01-16/?utm_source=openai))
Earlier this year, in January 2025, the Federal Circuit had reinstated a pause on MSN’s generic launch, reversing a previous decision that invalidated one of Novartis’ patents. Novartis argued that this ruling maintained its exclusive rights to sell Entresto until July. However, with the recent Delaware court decision and the impending expiration of pediatric exclusivity on July 15, 2025, Novartis faces significant challenges in maintaining its market share against generic competition. ([lathropgpm.com](https://www.lathropgpm.com/insights/federal-circuit-upholds-validity-of-entresto-patent-in-precedential-decision-concerning-written-description-and-enablement/?utm_source=openai))
The outcome of the Federal Circuit’s forthcoming decision will be pivotal for Novartis as it seeks to protect its flagship product from generic encroachment. Legal professionals and industry stakeholders are closely monitoring this case, given its potential implications for patent litigation strategies and market dynamics in the pharmaceutical sector.